Results 151 to 160 of about 21,298 (206)

Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. [PDF]

Cancer Res
Sottnik JL, Shackleford MT, Nesiba CS, Richer AL, Fleischmann Z, Swartz JM, Rowland CE, Musick M, Fu R, Myler LR, Opresko PL, Mehrotra S, Sokol ES, Hesselberth JR, Diamond JR, Sikora MJ.   +15 more
europepmc   +1 more source

Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies. [PDF]

Breast Cancer (Dove Med Press)
Pogoda K, Pawlik H, Balata A, Czopowicz M, Bak A, Twardowska I, Meluch M, Wojda M, Mlodzinska A, Szombara E, Sienkiewicz R, Konieczna A, Brewczynska E, Lemanska I, Majstrak-Hulewska A, Gorniak A, Niwinska A, Nowecki Z.   +17 more
europepmc   +1 more source

Selective Estrogen Receptor Degraders Induce Bradycardia by Modulating Nuclear Estrogen Signaling. [PDF]

JACC Basic Transl Sci
Basu S, Rosas Diaz AN, Narvaez-Paliza JM, Curtin C, Kurella S, Urias M, More Verde L, Patel JM, Asnani A.   +8 more
europepmc   +1 more source

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA. [PDF]

Technol Cancer Res Treat
Zeng H, Song LY, Guo R, Ding D, Zeng X, Liu Q.   +5 more
europepmc   +1 more source

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Rugo HS, Kaklamani V, McArthur H, Wander SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E, Maitland J, Kloss S, Wasserman T, Tolaney SM.   +12 more
europepmc   +1 more source

Vulvar Metastasis from Breast Cancer Treated with Abemaciclib plus Fulvestrant: A Case Report. [PDF]

Case Rep Oncol
Vanden Berghe C, Laka Antxustegi A, Nicaise N, Vander Borght T, D'Hondt L, Moerman J, de Codt M.   +6 more
europepmc   +1 more source

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. [PDF]

CA Cancer J Clin
Singareeka Raghavendra A, Damodaran S, Barcenas CH, Fuqua SA, Layman RM, Tripathy D.   +5 more
europepmc   +1 more source

CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. [PDF]

NPJ Breast Cancer
House NC, Chen MM, Khazaei S, Brown V, Ramsden P, Peng DH, Moore S, Yuan L, Wu R, Wang F, Luo L, Feng N, Bristow CA, Yap TA, Keyomarsi K, Marszalek JR, Ribich S, Rinne ML, Muthuswamy LB, Faia KL.   +19 more
europepmc   +1 more source

Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. [PDF]

Transl Breast Cancer Res
Stravodimou A, Voutsadakis IA.
europepmc   +1 more source

Navigating Treatment Sequencing in Advanced HR+/HER2- Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. [PDF]

Int J Mol Sci
Narvaez DP, Cescon DW.
europepmc   +1 more source